A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With ITP
Status:
Completed
Trial end date:
2019-04-09
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine safety, efficacy, tolerability and Pharmacokinetics
of ARGX-113 in Patients with Primary Immune Thrombocytopenia.